Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Innocrin Pharmaceuticals
4505 Emperor Boulevard, Suite 240
Durham, NC 27703
Phone: 919-237-9536
www.innocrinpharma.com

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia. Innocrin's investors include Novartis Venture Fund, Eshelman Ventures, Lilly Ventures, Hatteras Venture Partners, Intersouth Partners, Lurie Holdings, and Astellas Venture Management.

Key Contact
Name
William Moore
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
04/15/15 $28,000,000 Series D A&B Equity Holdings
Eshelman Ventures
Hatteras Venture Partners
Intersouth Partners
Novartis Venture Funds
undisclosed